For the quarter ending 2025-12-31, ROIV made $1,999K in revenue. -$265,891K in net income. Net profit margin of -13301.20%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | 1,999 | 1,571 | 2,170 | -39,572 |
| Cost of revenues | 700 | 111 | 154 | -3,560 |
| Research and development (includes 18,123and 9,685 of share-based compensation expense for the three months ended december 31, 2025 and 2024 and 40,218and 30,128 for the nine months ended december 31, 2025 and 2024, respectively) | 165,380 | 164,568 | 152,919 | 132,537 |
| Acquired in-process research and development | - | - | - | 0 |
| General and administrative (includes 86,874 and 69,386 of share-based compensation expense for the three months ended december 31, 2025 and 2024 and 228,778 and 165,670 for the nine months ended december 31, 2025 and 2024, respectively) | 175,072 | 143,125 | 134,019 | 98,465 |
| Total operating expenses | 341,152 | 307,804 | 287,092 | 227,442 |
| Gain on sale of telavant net assets | 0 | 0 | 0 | 0 |
| Loss from operations | -339,153 | -306,233 | -284,922 | -267,014 |
| Change in fair value of investments | 21,592 | 128,501 | -19,125 | 12,899 |
| Change in fair value of liability instruments | 24,416 | -20,959 | -2,329 | 11,583* |
| Gain on deconsolidation of subsidiaries | - | - | - | 3,108* |
| Interest income | 43,266 | 45,341 | 48,322 | -48,788* |
| Other (income) expense, net | 8,342 | -5,694 | -11,208 | -4,627 |
| Loss from continuing operations before income taxes | -290,369 | -159,044 | -269,262 | -292,839 |
| Income tax expense (benefit) | 23,332 | 6,995 | 4,649 | 48,629 |
| Loss from continuing operations, net of tax | -313,701 | -166,039 | -273,911 | -199,499* |
| Revenue, net | - | - | - | 32,995* |
| Cost of revenues | - | - | - | -410* |
| Research and development | - | - | - | 6,898* |
| Selling, general and administrative | - | - | - | 13,000* |
| Total operating expenses | - | - | - | 19,487* |
| Gain from operations | - | - | - | 13,508* |
| Loss on sale of subsidiary interests | - | - | - | -188,252* |
| Change in fair value of debt | - | - | - | 130,367* |
| Interest expense | - | - | - | 4,821* |
| Other income, net | - | - | - | -2,955* |
| Income (gain) from discontinued operations before income taxes | - | - | - | -52,154* |
| Income tax expense | - | - | - | 721* |
| Income from discontinued operations, net of tax | 0 | 0 | 0 | -52,875* |
| Net (loss) income | -313,701 | -166,039 | -273,911 | -252,375 |
| Net loss attributable to noncontrolling interests | -47,810 | -52,520 | -50,556 | -45,900 |
| Net (loss) income attributable to roivant sciences ltd | -265,891 | -113,519 | -223,355 | -206,475 |
| Basic EPS | -0.38 | -0.17 | -0.33 | -0.292 |
| Diluted EPS | -0.38 | -0.17 | -0.33 | -0.312 |
| Basic Average Shares | 696,859,682 | 680,947,866 | 680,286,922 | 707,578,996 |
| Diluted Average Shares | 696,859,682 | 680,947,866 | 680,286,922 | 661,767,931 |
Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (ROIV)